Citrofen^™ is a new, all natural patented (U.S. Patent No. 6,184,246) proprietary combination of two plant extracts that have been shown in previous animal studies to have unique anti-inflammatory properties. In a double-blind, placebo-controlled clinical trial with 80 overweight and normal subjects with knee osteoarthritis, Citrofen^™ demonstrated a highly significant (p<0.001) reduction in the LAI of the overweight group (46%) and the normal weight group (32%). LAI is a standard index for measuring pain or discomfort at rest and during various activities.

Citrofen™ also significantly (p<0.001) reduced C-reactive Protein (CRP) in the overweight group by 48% at 8 weeks and in the normal weight group by 44% (p<0.001). C-reactive protein, an indicator of inflammation, is now considered to be a positive risk factor for coronary artery disease. In addition, Citrofen™ significantly (p<0.001) lowered weight and BMI by 5% in the osteoarthritis subjects that were overweight. Weight loss plus significant improvement in comfort and mobility make Citrofen™ a true breakthrough product!